Showing results (31-40 of 49) with videos related to
Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2010
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimensVicente Valero, John Forbes, Mark D Pegram, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast CancerParvin F Peddi, Peter A Fasching, Duan Liu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapyMichael F Press, Guido Sauter, Marc Buyse, et al.The Oncologist|July 2, 2013
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 StudyHeather-Jane Au, Wolfgang Eiermann, Nicholas J Robert, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2016
HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical TrialsMichael F Press, Guido Sauter, Marc Buyse, et al.The Lancet. Oncology|December 14, 2011
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLuca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2007
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98Alan S Coates, Aparna Keshaviah, Beat Thürlimann, et al.The Lancet. Oncology|May 16, 2016
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trialLuca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, et al.Molecular Oncology|November 24, 2021
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trialTiziana Triulzi, Giampaolo Bianchini, Serena Di Cosimo, et al.The New England Journal of Medicine|October 14, 2011
Adjuvant trastuzumab in HER2-positive breast cancerDennis Slamon, Wolfgang Eiermann, Nicholas Robert, et al.Pageof 5